Non-regulatory
On August 30, 2018, at 07:00 am CET, Sedana Medical AB (publ) (Sedana Medical or the Company) will publish its interim report for the second quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which wil…
Regulatory
Sedana Medical AB (publ) (Sedana Medical or the Company) announces today that the Company has received approval from the central ethical committee for its pivotal phase 3-study in Germany, IsoConDa, to continue to use the original study protocol afte…
Regulatory
Sedana Medical AB (publ), developing and marketing the medical device AnaConda and volatile anesthetics for sedation of mechanically ventilated intensive care unit (ICU) patients, today announced the recruitment of Gunilla Mickelsson as Global Market…
Regulatory
Sedana Medical AB (publ) (”Sedana Medical” or the ”Company”), today announces that the Company has successfully completed a directed new share issue of approximately SEK 112 million.
Regulatory
Sedana Medical AB (publ) (”Sedana Medical” or the ”Company”) today announces its intention to execute a directed new share issue to Swedish and international investors (the ”Private Placement”). The Company has appointed Pareto Securities AB (”Pareto…
Regulatory
Sedana Medical AB (publ) held the annual general meeting on 22 May 2018 in Stockholm. Below follows a summary of the resolutions that were made during the meeting.
Non-regulatory
On May 22, 2018, at 12:30 pm CET, Sedana Medical AB (publ) (Sedana Medical or the Company) will publish its interim report for the first quarter 2018. All interested parties are invited to participate in a web-cast telephone conference, which will in…
Regulatory
Sedana Medical´s Annual Report for 2017 has been published and is available on www.sedanamedical.com.
Regulatory
Sedana Medical AB ("Sedana Medical or the Company") reports a more than expected 60% increase in sales in the first quarter of 2018 compared to the corresponding period in 2017.
Regulatory
Sedana Medical AB ("Sedana Medical or the Company") announces that the schedule for patient recruitment in the ongoing Phase 3 IsoConDa study is likely to be extended.
Regulatory
Sedana Medical AB (publ) hereby convenes the Annual General Meeting 2018. The shareholders in Sedana Medical AB (publ) are hereby summoned to attend the Annual General Meeting on Tuesday 22 May 2018 at 4 p.m. at. Erik Penser Bank, Apelbergsgatan 27,…
Non-regulatory
Sedana Medical AB (publ) today announces the Nomination Committee's proposal for a new Board of Directors for the 2018 Annual General Meeting. The Nomination Committee 2017-2018 consists of representatives of the four largest shareholders at the end…
Non-regulatory
Sedana Medical AB (“Sedana Medical” or “the Company”) is recruiting Norwegian and Danish Sales Manager and is thus established in Norway and Denmark with its own direct sales business from March 1st, 2018.
Regulatory
Sedana Medical AB (publ) informs today a change of Certified Adviser from Pareto Securities AB to Erik Penser Bank as of January 1st, 2018
Regulatory
Financial summary July-September · Net sales during the third quarter amounted to 10,191 (7,603) KSEK, corresponding to an increase of 34% compared with the same period in 2016. · Earnings before interest, taxes, depreciation and amortisat…
Regulatory
Sedana Medical AB (”Sedana Medical” and “the Company”) has today submitted the application for registration of the medical device AnaConDa in Japan through its Japanese distributor.
Non-regulatory
Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 19, 2017, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes t…
Non-regulatory
Sedana Medical AB (publ), developing and marketing the medical device AnaConda and volatile anesthetics for sedation of mechanically ventilated intensive care unit (ICU) patients, announced the recruitment of Peter Sackey, MD, PhD as Chief Medical Of…